Skip to main content

Table 1 Patient baseline characteristics, efficacy population

From: Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE)

Characteristic

n (%)

Patients, n (%)

3430 (100)

Gender, n (%)

 

 Male

1993 (58.1)

 Female

1387 (40.4)

Mean age, years ± SD (range); n = 3322

53.4 ± 10.4 (19.0–89.0)

Age, n (%)

 

 <65 years

2836 (82.7)

 ≥65 years

486 (14.2)

Race, n (%)

 

 Asian

1212 (35.3)

 White

966 (28.2)

 Black

96 (2.8)

 Other

970 (28.3)

Mean BMI, kg/m2 ± SD (range); n = 3214

29.9 ± 5.2 (15.1–57.4)

Mean BP, mm Hg ± SD (range)

 

 SBP [n = 3413]

166.4 ± 16.7 (100.0–260.0)

 DBP [n = 3418]

99.7 ± 9.9 (55.0–170.0)

Stages of hypertension, n (%)a

 

 Normal

8 (0.2)

 High normal

16 (0.5)

 Grade 1 (mild)

407 (11.9)

 Grade 2 (moderate)

1620 (47.2)

 Grade 3 (severe)

1142 (33.3)

 Isolated systolic hypertension

218 (6.4)

Duration of hypertension, n (%); n = 3426

 

 Newly diagnosed

479 (14.0)

 Previously diagnosed

2947 (85.9)

  <1 year

434 (14.7)

  1–5 years

1210 (41.1)

  6–10 years

692 (23.5)

  >10 years

554 (18.8)

Previous antihypertensive therapy, n (%)

 

 0

421 (12.3)

 1

1314 (38.3)

 2

1067 (31.1)

 ≥3

521 (15.2)

Previous classes of antihypertensive therapy, n (%); n = 2922b

 

 ACE inhibitors

1210 (41.4)

 ARBs

833 (28.5)

 CCBsc

348 (11.9)

 β-blockers

1389 (47.5)

 Thiazide diuretics

940 (32.2)

 Other

97 (3.3)

Smoking history, n (%)

 

 Current smoker

725 (21.1)

 Never

1940 (56.6)

 Past smoker

606 (17.7)

  1. Data for all variables were not available for all patients
  2. ACE angiotensin-converting enzyme, ARBs angiotensin II receptor blockers, BMI body mass index, CCBs calcium channel blockers, DBP diastolic blood pressure, GITS gastrointestinal therapeutic system, SBP systolic blood pressure, SD standard deviation
  3. aDefinitions according to ESH/ESC 2007 guidelines. bMultiple responses possible. cOther than nifedipine GITS